Abstract:Efforts in cancer immunotherapy aim to counteract evasion mechanisms and stimulate the immune system to recognise and attack cancer cells effectively. Combination therapies that target multiple aspects of immune evasion are being investigated to enhance the overall efficacy of cancer immunotherapy. PD-1 (Programmed Cell Death Protein 1), CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), LAG-3 (Lymphocyte-Activation Gene 3), and TIM-3 (T Cell Immunoglobulin and Mucin Domain-Containing Protein3) are all immune checkpoint receptors that play crucial roles in regulating the immune response and maintaining self-tolerance often exploited by cancer cells to evade immune surveillance. Antibodies targeted against immune checkpoint inhibitors such as anti-PD-1 antibodies (e.g., pembrolizumab, nivolumab), anti-CTLA-4 antibodies (e.g., Ipilimumab), and experimental drugs targeting LAG-3 and TIM-3, aim to block these interactions and unleash the immune system's ability to recognise and destroy cancer cells. The US FDA has approved different categories of immune checkpoint inhibitors that have been utilised successfully in some patients with metastatic melanoma, renal cell carcinoma, head and neck cancers, and non-small lung cancer. Although several immune checkpoint inhibitor antibodies have been developed, they exhibited immune-related adverse effects, resulting in hypophysitis, diabetes, and neurological issues. These adverse effects of antibodies can be reduced by developing aptamer against the target. Aptamers offer several advantages over traditional antibodies, such as improved specificity, reduced immunogenicity, and flexible design for reduced adverse effects that specifically target and block protein-protein or receptor-ligand interactions involved in immune checkpoint pathways. The current study aims to review the function of particular immune checkpoint inhibitors along with developed aptamer-mediated antitumor cytotoxicity in cancer treatment.

An overview of immune checkpoint therapy in autoimmune diseases

Immune Checkpoints as Therapeutic Targets in Autoimmunity

Immune checkpoint molecules. Possible future therapeutic implications in autoimmune diseases

A comprehensive review of immune checkpoint inhibitors for cancer treatment

Immune-related adverse effects of checkpoint immunotherapy and implications for the treatment of patients with cancer and autoimmune diseases

Tumor Immune Checkpoints and Their Associated Inhibitors

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1

Immune checkpoint inhibitors: breakthroughs in cancer treatment

Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases

Immune checkpoint signaling and cancer immunotherapy

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review

Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.

Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy

Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

Immune checkpoint inhibitors: recent progress and potential biomarkers

Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview

Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy

[Immune-checkpoints: the new anti-cancer immunotherapies]

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer